Sign In
Buy CKPT
$4.26
+0 (+0%)
At Close: Aug 29, 2025
Is Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Being Overpaid?
11:43am, Tuesday, 31'st Dec 2019
James Oliviero has been the CEO of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) since 2015. This report will, first...
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
12:22pm, Thursday, 21'st Nov 2019
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(anno
Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock
02:20pm, Wednesday, 20'th Nov 2019
Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offer
Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock
09:01pm, Tuesday, 19'th Nov 2019
Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditi
NEW YORK, Nov. 08, 2019 -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new.
Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
09:30pm, Thursday, 07'th Nov 2019
NEW YORK, Nov. 07, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial.
Did You Manage To Avoid Checkpoint Therapeutics's (NASDAQ:CKPT) 25% Share Price Drop?
01:33pm, Sunday, 27'th Oct 2019
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC)40% objective response rate observed in non-small cell lung cancerWell-tolerated safety profile.
Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
12:30pm, Thursday, 26'th Sep 2019
NEW YORK, Sept. 26, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,.
This medical student scored a 281 on the USMLE Step 2 CK. You can, too
09:00pm, Wednesday, 21'st Mar 2018
Some tips for getting a high score on this important test.
